Xenon Pharmaceuticals Inc. (XENE) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, XENE scores 37 out of 100 and carries a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 8 / 20. Per the RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -7.7%. For a prospective investor, this is the weakest operating read: the business is consuming capital rather than generating it, so any valuation case must rest on future cash generation that the current data does not demonstrate.
• Whale 13F Flow: 4 / 20. The RQD rating's institutional accumulation and options positioning reading is the lowest pillar. Per the source, the holders section is empty, so the underlying flow cannot be independently verified here; the low score signals weak institutional conviction as measured by the rating.
• Insider Conviction: 5 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scores low. The source data contains no insider trade detail, so the score cannot be decomposed further.
• Macro Regime Fit: 6 / 20. Per the RQD rating, beta of 1.1 and sector sensitivity produce a modest score. The stock is slightly more volatile than the market, which amplifies both upside and drawdown.
• Forensic Balance Sheet: 14 / 20. Per the RQD rating, Altman Z 26, Piotroski F 5/9, and Debt/Equity 0.04 form the strongest pillar. Leverage is minimal and solvency metrics are favorable, meaning the near-term risk is burn rate rather than debt.

Investor implications: the rating points to a company with low financial leverage but deeply negative operating economics. Upside depends on a sustained shift toward cash generation; the valuation tradeoff is that a forward P/E of 29 (per market data) prices in expectations the trailing numbers do not yet show. This is an analytical framing, not personalized advice.

Xenon Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $3.6B. The source data does not describe its products, customers, or revenue model. Reported revenue for FY 2025 is $0.0M, so the company does not currently generate revenue in the reported periods.

Per the SEC financials, losses widened each year across the three periods, with FY 2025 operating income of $-373.1M. Gross margin is 0%, operating margin is -36.7%, and net margin is -34% per market data, with ROIC at -35%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Cash rose from $142.7M to $199.2M while debt declined from $467.9M (FY 2023) to $23.1M (FY 2025), indicating a strengthened balance sheet despite continued cash burn.

Six news items reference XENE, all tagged YELLOW under the MARKET WIRE impact label. Headlines are generic market-coverage pieces (Yahoo Finance, Benzinga, Stock Titan, and others) describing price action, institutional positioning, and fundamental catalysts without specific event detail. Benzinga's item references a Q2 2026 earnings call transcript. Stock Titan reports that nine new employees received options to buy shares at $37.54 each. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded. Risk watch items: negative earnings, ongoing cash burn, and the stock sitting in the lower portion of its 52-week range.

Per the Butterfly Supply-Chain Graph, supply chain is recorded as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. An investor should note that the absence of recorded links is a data gap, not evidence of independence.

• What products or pipeline assets drive XENE's cash burn, and what are their development timelines?
• What does the Q2 2026 earnings call transcript disclose about spending trajectory and runway?
• Why is the trailing P/E unavailable while forward P/E is 29, and what earnings inflection supports that estimate?
• What is the source of the debt reduction from $467.9M to $23.1M, and what are the remaining obligations?
• Who are the institutional and insider holders, given that the holders section is empty?